Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 412-419 , September 2010

Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment

  • Danielle C. Whitehair

      Affiliations

    • Department of Neurosciences, University of California, San Diego, CA, USA
    • ,
  • Abdullah Sherzai

      Affiliations

    • Loma Linda University Medical Center, Riverside, CA, USA
    • ,
  • Jennifer Emond

      Affiliations

    • Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
    • ,
  • Rema Raman

      Affiliations

    • Department of Neurosciences, University of California, San Diego, CA, USA
    • Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
    • ,
  • Paul S. Aisen

      Affiliations

    • Department of Neurosciences, University of California, San Diego, CA, USA
    • ,
  • Ronald C. Petersen

      Affiliations

    • Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Adam S. Fleisher

      Affiliations

    • Banner Alzheimer's Institute, Phoenix, AZ, USA
    • Corresponding Author InformationCorresponding author. Tel.: 602 239-6979; Fax: 602 239-6499.
    • ,
  • Alzheimer's Disease Cooperative Study

References 

  1. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13:45–53
  2. Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry. 2006;77:429–438
  3. Gauthier S. Cholinesterase inhibitors in late-stage Alzheimer's disease. Lancet Neurol. 2006;5:468–469
  4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308
  5. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274–1278
  6. Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004;62:1990–1995
  7. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol. 2005;62:975–980
  8. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  9. Tierney MC, Szalai JP, Snow WG, Fisher RH, Tsuda T, Chi H, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149–154
  10. Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, et al. Apolipoprotein e gene variability and cognitive functions at age 79: a follow-up of the Scottish mental survey of 1932. Psychol Aging. 2004;19:367–371
  11. Hofer SM, Christensen H, Mackinnon AJ, Korten AE, Jorm AF, Henderson AS, et al. Change in cognitive functioning associated with apoE genotype in a community sample of older adults. Psychol Aging. 2002;17:194–208
  12. Packard CJ, Westendorp RGJ, Stott DJ, Caslake MJ, Murray HM, Shepherd J, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc. 2007;55:1777–1785
  13. Smith JD. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev. 2002;1:345–365
  14. Swan GE, Lessov-Schlaggar CN, Carmelli D, Schellenberg GD, La Rue A. Apolipoprotein E epsilon4 and change in cognitive functioning in community-dwelling older adults. J Geriatr Psychiatry Neurol. 2005;18:196–201
  15. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol. 2002;59:1154–1160
  16. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76:1479–1484
  17. Bunce D, Fratiglioni L, Small BJ, Winblad B, Bäckman L. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology. 2004;63:816–821
  18. Pendleton N, Payton A, van den Boogerd EH, Holland F, Diggle P, Rabbitt PMA, et al. Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults. Neurosci Lett. 2002;324:74–76
  19. Yip AG, Brayne C, Easton D, Rubinsztein DC. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J Med Genet. 2002;39:639–643
  20. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006;66:828–832
  21. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  22. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133–1142
  23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology. 1984;34:939–944
  24. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68:1588–1595
  25. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  26. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356–1364
  27. Mohs RC. The Alzheimer's disease assessment scale. Int Psychogeriatr. 1996;8:195–203
  28. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12:168–179
  29. Smith A. Symbol Digit Modalities Test Manual (revised). Los Angeles, CA: Western Psychological Services; 1982;
  30. Monsch AU, Bondi MW, Butters N, Salmon DP, Katzman R, Thal LJ. Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol. 1992;49:1253–1258
  31. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S13–S21
  32. Kaplan EF, Goodglass I, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea & Febiger; 1983;
  33. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. Rev. New York, NY: The Psychological Corporation, Harcourt Brace Jovanovich, Inc; 1981;
  34. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414
  35. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33–S39
  36. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136–1139
  37. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923
  38. Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord. 2001;12:379–386
  39. Visser PJ, Verhey FR, Ponds RW, Cruts M, Van Broeckhoven CL, Jolles J. Course of objective memory impairment in non-demented subjects attending a memory clinic and predictors of outcome. Int J Geriatr Psychiatry. 2000;15:363–372
  40. Ramakers IH, Visser PJ, Aalten P, Bekers O, Sleegers P, van Broeckhoven CL, et al. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. Dement Geriatr Cogn Disord. 2008;26:101–108
  41. Caselli RJ, Graff-Radford NR, Reiman EM, Weaver A, Osborne D, Lucas J, et al. Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology. 1999;53:201–207
  42. Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64:1306–1311
  43. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106:6820–6825
  44. Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel ST, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain. 2008;131:1252–1258
  45. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487–1494
  46. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70:191–199
  47. Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64:1853–1859

 For all authors there are no disclosures to be made of any financial support from, or equity positions in, manufacturers of drugs or products mentioned in the manuscript. These authors and the Alzheimer's Disease Cooperative study had full publication rights without influence or restrictions from the Institute for the Study of Aging, Pfizer Inc., or Eisai Inc. All authors have agreed to conditions noted on the Author Disclosure Form. All of the authors have been instrumental in the interpretation and presentation of data in this paper. This manuscript has not been simultaneously submitted for publication to any other journal.

 Financial disclosure: Danielle C. Whitehair, Jennifer Emond, Rema Raman, Adam S. Fleisher: none. Abdullah Sherzai is a speaker for Novartis (Exelon patch); Paul S. Aisen consults with pharmaceutical companies regarding AD drug development, including Elan, Wyeth, Eisai, Neurochem, Schering-Plough, Bristol Myers Squibb, Lilly, Neurophage, Merck, Roche, Amgen, Genentech, Abbott, Pfizer, Novartis and Medivation; Ronald C. Petersen consults with pharmaceutical companies regarding AD drug development, including Elan, GE Healthcare and Wyeth. He also is a speaker for Eisai, Janssen, Novartis and Pfizer.

PII: S1552-5260(10)00002-6

doi: 10.1016/j.jalz.2009.12.003

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 412-419 , September 2010

Article Tools

* Image Usage & Resolution